Phio Pharmaceuticals Corp. (PHIO) News
Follow Phio Pharmaceuticals Corp. (PHIO) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 6 public stories across 5 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
M
Phio Pharmaceuticals Director Acquires $9,822.60 in Common Shares
EQUITY | Nov 16, 2026, 03:31 PM UTC
M
Phio Pharmaceuticals Reports Third-Quarter 2026 Results and PH-762 Update
Phio Pharmaceuticals reported third-quarter 2026 financial results and said PH-762 reached development milestones, including cGMP manufacturing completion, treatment in a long-term toxicology study and submission of regu
EQUITY | Nov 05, 2026, 09:25 PM UTC
L
Phio Pharmaceuticals to Present Clinical Development Update and Upcoming Catalysts at Life Sciences Future 2026 Conference
Company to Highlight Next Stage of PH-762 Clinical Development in Cutaneous Squamous Cell CarcinomaKing of Prussia, Pennsylvania--(. - September 23, 2026) - Phio Pharmaceuticals Corp. NASDAQ:PHIO, a clinical-stage biopha
NEWS | Sep 23, 2026, 11:01 AM UTC
M
PHIO Manufacturing PH-762
Phio Pharmaceuticals commences manufacturing the first commercial-scale batch of PH-762 drug substance at Nitto Denko Avecia
EQUITY | Jun 24, 2026, 11:07 AM UTC
M
PHIO Advances PH-762
Phio Pharmaceuticals reaches key milestone in advancing lead candidate PH-762
EQUITY | Jun 24, 2026, 11:04 AM UTC